速崩壊錠に対する軽度嚥下障害患者の評価
スポンサーリンク
概要
- 論文の詳細を見る
Rapidly disintegrating tablets ("EMP-tablet", developed by Eisai, Co., Ltd.) are developed based on a formulation that is expected to make the swallowing of medicines easier for patients with mild dysphagia. To evaluate the sensation of the oral administration of such "EMP-tablets", the authors conducted a study in patients with mild dysphagia. After the administration of both "EMP-tablets" and uncoated compressed tablets of consisting of the same components and the same appearance (plain tablet), the sensation of their oral administration and other benefits such as size and so on, were compared for both tablets. The 25 subjects with mild dysphagia, who participated in the trial were asked to respond to the question "which tablet was easier to swallow?". The rate of positive responses for the "EMP-tablet" was 76%, which was significantly better (p=0.0013) than the response for the "plain tablet". Regarding the question about the size of a tablet, although only 28% responded "It is no problem" before oral administration, the response improved to 80% after oral administration. In addition, there was also a statistically significant difference (p=0.0096) in the ratio of patients who required less water for the oral intake of "EMP-tablets" than "plain tablets"(60% vs 16%). Consequently, in patients with mild dysphagia, the clinical benefits of "EMP-tablets" were clearly observed regarding the level of satisfaction during oral administration (tablet size and so on, as well as the required amount of drinking water) in comparison to "plain tablets".
- 日本医療薬学会の論文
- 2003-10-10
著者
関連論文
- P-463 チョコレート風味の口腔内速崩錠(チョコレット)の開発に関する研究 (No.4) チョコレット・プラセボ錠の調製と製剤物性の評価 (2)
- 癌化学療法時にみられる口内炎発症予防を目的としたメシル酸カモスタット口腔内崩壊錠の調製と評価
- 遺伝子組換えヒト組織性Plasminogen Activator (rt-PA) 誘導体 (E6010) の体内動態に関する研究 (1) : ラットに ^I-標識E6010を単回静脈内投与した時の血中濃度推移, 分布, 代謝および排泄の ^I-標識 rt-PAとの比較検討
- 幼若犬および成熟犬におけるセファロスポリン誘導体の体内動態の比較
- 速崩壊錠に対する軽度嚥下障害患者の評価
- ビーグル犬の胃内pHの測定およびコントロール